$CORT

JPMorgan BetaBuilders US Small Cap ETF (BBSC) Adds Corcept, Elas

JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) added 171 positions on Monday, deploying $161.2 million in net purchases. Its largest buys were Corcept Therapeutics (CORT) at $3.3 million, Elastic NV (ESTC) at $2.2 million, and SentinelOne (S) at $2.2 million. BBSC holds 804 stocks with a 0.09% expense ratio and a 14.66% year-to-date return.

Original reporting
Published Sep 30, 2026, 10:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 10:36 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT · $ESTC · $S · $CVLT · $QLYS · $BBSC
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosed purchases represent fresh capital allocation to small‑cap and mid‑cap tech stocks, but the dollar amounts are modest relative to the fund's $709M AUM, limiting immediate market impact.

02

Market read

Routine fund activity; modest upside potential for the five newly added stocks.

03

What to watch

Potential future sector rebalancing or fund turnover could reverse these positions quickly.

Relevance 4/10Novelty 2/10Timing: same day

Background

JPMorgan BetaBuilders US Small Cap ETF (BBSC) reported its latest holdings update, adding five new positions without any sales.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

BBSC added a new $3.3M position in Corcept Therapeutics, its largest buy of the day.

Expected impact

potential slight upside as the fund adds a new position

Evidence & confidence

New $3.3M buy represents 0.49% of the fund, indicating fresh demand but limited scale.

$ESTCNeutralMedium confidence
Context

BBSC opened a $2.2M position in Elastic NV, one of its top new holdings.

Expected impact

possible modest upside from fresh demand

Evidence & confidence

The $2.2M buy is a new stake (0.33% of fund), likely to generate limited price pressure.

$SNeutralMedium confidence
Context

BBSC added a $2.2M new position in SentinelOne, its third largest buy.

Expected impact

minor upside as the fund builds a new position

Evidence & confidence

New $2.2M stake (0.32% of fund) signals fresh interest but modest impact.

$CVLTNeutralMedium confidence
Context

BBSC opened a $1.8M new position in Commvault Systems.

Expected impact

slight upside from the new allocation

Evidence & confidence

The $1.8M purchase (0.27% of fund) is a modest addition.

$QLYSNeutralMedium confidence
Context

BBSC added a $1.7M new position in Qualys Inc.

Expected impact

minor upside as the fund takes a new stake

Evidence & confidence

The $1.7M buy (0.26% of fund) is a small but fresh demand source.

Market effects

Small‑cap and mid‑cap tech exposure slightly increased across the fund.

U.S. equity market sees modest buying pressure in the listed stocks.

Limited; impact confined to the individual securities mentioned.

Counterpoint

The ETF's buying may be already priced in; other investors could view the additions as overbought.

Key entities

  • JPMorgan BetaBuilders US Small Cap ETF

    Fund that made the disclosed purchases.

  • Corcept Therapeutics

    Largest new holding for BBSC at $3.3M.

Related articles

$SMed

SentinelOne downgraded at FBN on CrowdStrike concerns

FBN Securities downgraded SentinelOne to Sector Perform, citing competition from CrowdStrike. The firm noted SentinelOne's improved margins and growth but highlighted CrowdStrike's larger market share and spending capacity. SentinelOne's ARR reached $1.22B, compared to CrowdStrike's $5.84B and Palo Alto Networks' $9.10B.

$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

$CORTHighAI 9/10

Corcept Therapeutics Incorporated: Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant)

Corcept Therapeutics (CORT) announced the European Medicines Agency's CHMP recommended EU approval for relacorilant, combined with nab-paclitaxel, to treat platinum-resistant ovarian cancer. The recommendation follows positive Phase 2 and Phase 3 trial results showing improved survival rates. The EC will decide by Q4 2026. Relacorilant is already FDA-approved in the U.S. for the same indication.